aTyr Pharma (471A) Price & Analysis

13 Followers

471A Stock Chart & Stats

€0.34

-€0.02(-5.92%)

At close: Jul 27 4:00 PM EDT

€0.34

-€0.02(-5.92%)

Day’s Range― - ―

52-Week Range€0.25 - €5.60

Previous CloseN/A

Volume0.00

Average Volume (3M)400.00

Market Cap

€41.29M

Enterprise Value€21.47

Total Cash (Recent Filing)€66.51M

Total Debt (Recent Filing)€11.70M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Aug 12, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.73

Shares Outstanding98,051,210

10 Day Avg. Volume500

30 Day Avg. Volume400

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)1.08

Price to Sales (P/S)383.25

P/FCF Ratio-1.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€2.71

Price Target Upside696.70% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.49

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthModest leverage and positive equity provide a structural buffer against near-term shocks, reducing immediate insolvency risk. This gives management runway to continue clinical development and execute trial programs without severe debt-driven constraints, though funding needs remain.

Global Rights ConsolidationRegaining worldwide rights to efzofitimod consolidates regulatory, clinical and IP control, simplifying development strategy and potential commercialization planning. This structural ownership removes partner-driven fragmentation and improves strategic optionality for global trials and future deals.

Regulatory Clarity And Phase 3 PathClear FDA guidance on functional and symptom endpoints plus a defined Phase 3 protocol materially reduces regulatory uncertainty. A well-specified 372-patient global study with agreed measures strengthens the development path and supports credible registration prospects over the coming months.

Bears Say

Heavy Cash BurnSustained negative operating and free cash flow at this magnitude is a structural funding pressure that will likely require additional capital raises. Recurrent cash burn increases dilution risk, constrains strategic flexibility, and can force program delays or cutbacks if financing conditions tighten.

Negligible Revenue / Persistent LossesMinimal commercial revenue and large, persistent losses indicate the company is still pre-revenue and reliant on external funding. This structural lack of operating cash generation heightens financing dependency and makes long-term sustainability contingent on clinical success or partner deals.

Listing And Shareholder OverhangOngoing minimum bid-price noncompliance creates a persistent governance and listing risk over the medium term. Potential reverse-split choices or delisting proceedings could complicate capital raises, corporate planning and shareholder confidence, constraining strategic options until resolved.

aTyr Pharma News

aTyr Pharma Regains Global Rights to Efzofitimod

aTyr Pharma ( ($ATYR) ) has shared an announcement. On May 12, 2026, aTyr Pharma received notice from...

3d ago

ATYR

aTyr Pharma Lawsuit: Company Asks Court to Dismiss Investor Securities Claims

aTyr Pharma (ATYR) and two executives have asked a federal court to dismiss an amended investor lawsuit over statements...

6d ago

ATYR

Joseph Pantginis Reiterates Hold as Efzofitimod Shifts to Restrictive Lung Phenotype After Mixed Phase 3 EFZO-FIT Results

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on ATYR stock, giving a Hold rating today....

18d ago

ATYR

aTyr Pharma Granted Nasdaq Extension to Regain Compliance

aTyr Pharma ( ($ATYR) ) has provided an announcement. On December 4, 2025, aTyr Pharma, Inc. disclosed that...

2M ago

ATYR

Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis

Atyr Pharma Inc. ($ATYR) announced an update on their ongoing clinical study. The Phase 3 study “A Phase...

2M ago

ATYR

aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data

aTyr Pharma ( ($ATYR) ) has issued an announcement. aTyr Pharma has updated investors on its strategy to...

2M ago

ATYR

aTyr Pharma upgraded to Buy from Hold at Freedom Broker

Freedom Broker upgraded aTyr Pharma (ATYR) to Buy from Hold with a price target of $3.50, up from...

2M ago

ATYR

aTyr Pharma Inc options imply 30.5% move in share price post-earnings

Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 142:1. Implied volatility suggests...

3M ago

ATYR

Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports

The major averages were broadly lower near noon, giving back some of yesterday’s gains as tech stocks lag,...

3M ago

DLO

aTyr Pharma reports Q1 EPS (11c), consensus (15c)

“2026 is off to a productive start, as we now have a clear path forward for efzofitimod in...

3M ago

ATYR

Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program

JonesTrading analyst Boris Peaker has maintained their neutral stance on ATYR stock, giving a Hold rating today. Boris...

3M ago

ATYR

Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on ATYR stock, giving a Hold rating yesterday....

3M ago

ATYR

aTyr Pharma provides regulatory update on efzofitimod following Type C meeting

aTyr Pharma (ATYR) announced the path forward for efzofitimod, in pulmonary sarcoidosis, following the receipt of the official...

3M ago

ATYR

aTyr Pharma Announces New Phase 3 Sarcoidosis Trial

An announcement from aTyr Pharma ( ($ATYR) ) is now available. On May 11, 2026, aTyr Pharma reported...

3M ago

ATYR

471A FAQ

What was aTyr Pharma’s price range in the past 12 months?

aTyr Pharma lowest stock price was €0.25 and its highest was €5.60 in the past 12 months.

What is aTyr Pharma’s market cap?

aTyr Pharma’s market cap is €41.29M.

When is aTyr Pharma’s upcoming earnings report date?

aTyr Pharma’s upcoming earnings report date is Aug 12, 2026 which is in 9 days.

How were aTyr Pharma’s earnings last quarter?

aTyr Pharma released its earnings results on May 15, 2026. The company reported -€0.095 earnings per share for the quarter, beating the consensus estimate of -€0.114 by €0.019.

Is aTyr Pharma overvalued?

According to Wall Street analysts aTyr Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does aTyr Pharma pay dividends?

aTyr Pharma does not currently pay dividends.

What is aTyr Pharma’s EPS estimate?

aTyr Pharma’s EPS estimate is -0.1.

How many shares outstanding does aTyr Pharma have?

aTyr Pharma has 98,051,210 shares outstanding.

What happened to aTyr Pharma’s price movement after its last earnings report?

aTyr Pharma reported an EPS of -€0.095 in its last earnings report, beating expectations of -€0.114. Following the earnings report the stock price went up 45.817%.

Which hedge fund is a major shareholder of aTyr Pharma?

Currently, no hedge funds are holding shares in DE:471A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

aTyr Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-18.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

aTyr Pharma

aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.

aTyr Pharma (471A) Earnings & Revenues

Historic Earnings Reports

471A Stock 12 Month Forecast

Average Price Target

€2.71

▲(696.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","3":"€3","5":"€5","7":"€7","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.06762982,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.7087633125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.86680426,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.87</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.7621253707692307,1.2042507415384613,1.646376112307692,2.088501483076923,2.530626853846153,2.972752224615384,3.4148775953846147,3.8570029661538454,4.299128336923077,4.741253707692307,5.183379078461538,5.625504449230768,{"y":6.06762982,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.5037510240384615,0.6875020480769232,0.8712530721153846,1.0550040961538463,1.2387551201923077,1.4225061442307694,1.606257168269231,1.7900081923076925,1.973759216346154,2.1575102403846156,2.341261264423077,2.5250122884615385,{"y":2.7087633125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.36206186615384617,0.40412373230769233,0.4461855984615385,0.4882474646153846,0.5303093307692308,0.5723711969230769,0.614433063076923,0.6564949292307692,0.6985567953846155,0.7406186615384616,0.7826805276923077,0.8247423938461538,{"y":0.86680426,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.755,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.575,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.615,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.575,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.552,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.356,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.419,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >